MUMBAI, India, Oct. 26 -- Intellectual Property India has published a patent application (202611107335 A) filed by Chandigarh University on September 07, 2026, for Telmisartan Loaded Lipid Polymeric Hybrid Nanoparticles For Enhanced Bioavailability And Sustained Oral Drug Delivery.
Inventors include Shruti Sharma; Chandan Sharma; and Aditi.
The application for the patent was published on October 23, 2026, under issue no. 43/2026.
Abstract: The present invention relates to a lipid polymeric hybrid nanoparticle formulation comprising telmisartan for enhanced oral drug delivery. Telmisartan is characterized by poor aqueous solubility and limited oral bioavailability, which may result in variable absorption and reduced therapeutic effectiveness. The invention provides a hybrid nanocarrier comprising a polymeric matrix encapsulating telmisartan and a lipid layer surrounding the polymeric matrix. The combination of polymeric and lipid components enhances drug encapsulation, improves aqueous dispersion and dissolution, and provides controlled and sustained release of telmisartan. The hybrid nanoparticle formulation further improves the stability of the incorporated drug and facilitates enhanced gastrointestinal absorption, thereby increasing oral bioavailability and therapeutic efficacy. By integrating the advantageous properties of polymeric nanoparticles and lipid-based carriers, the invention provides an efficient and stable drug delivery platform for telmisartan. The formulation is suitable for reproducible pharmaceutical manufacturing and may be adapted for large- scale oral antihypertensive drug delivery applications.
Disclaimer: Curated by HT Syndication.
